EODData

MEMBERSHIP REGISTER LOG IN

FRA, BM8: BioMarin Pharmaceutical Inc

21 Aug 2026
LAST:

57.74

CHANGE:
 1.70		OPEN:
57.74		HIGH:
57.74		ASK:
0.00		VOLUME:
0
CHG(%):
2.86		PREV:
59.44		LOW:
57.74		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Aug 2657.7457.7457.7457.740
20 Aug 2659.4459.4459.4459.440
19 Aug 2657.1657.1657.1657.160
18 Aug 2656.6856.6856.6856.680
17 Aug 2657.8457.8457.7257.720
14 Aug 2659.0259.1058.0458.04144
13 Aug 2660.7460.7460.7460.740
12 Aug 2660.1860.6460.1860.640
07 Aug 2655.1655.1655.1655.160
06 Aug 2651.6051.6051.6051.600

PROFILE

Name:BioMarin Pharmaceutical Inc
About:BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Sector:Healthcare
Industry:Biotechnology
Address:770 Lindaro Street, San Rafael, CA, United States, 94901
Website:https://www.biomarin.com
ISIN:US09061G1013
LEI:NSLL8ITTRR0J5HEMR848

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:180.44 
Forward P/E:62.76 
PEG Ratio:-2.21 
Price to Sales:3.28 
Price to Book:2.05 
Profit Margin:0.02 
Operating Margin:0.21 
Return on Assets:0.03 
Return on Equity:0.01 
Revenue:2.911B 
EBITDA:572.94M 
Shares:192.02M 
Market Cap:11.087B 

TECHNICAL INDICATORS

MA5:57.750.0%
MA10:57.490.4%
MA20:55.174.7%
MA50:52.2410.5%
MA100:49.3816.9%
MA200:48.8118.3%
STO9:46.24
STO14:67.18
RSI14:59.02
WPR14:-32.82
MTM14:4.54
ROC14:0.09 
ATR:1.61 
Week High:59.442.9%
Week Low:56.681.9%
Month High:60.745.2%
Month Low:50.8218.3%
Year High:60.745.2%
Year Low:42.6235.5%